CL2016003276A1 - Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía. - Google Patents
Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía.Info
- Publication number
- CL2016003276A1 CL2016003276A1 CL2016003276A CL2016003276A CL2016003276A1 CL 2016003276 A1 CL2016003276 A1 CL 2016003276A1 CL 2016003276 A CL2016003276 A CL 2016003276A CL 2016003276 A CL2016003276 A CL 2016003276A CL 2016003276 A1 CL2016003276 A1 CL 2016003276A1
- Authority
- CL
- Chile
- Prior art keywords
- acetamide
- biphenyl
- vasculopathy
- nephropathy
- retinopathy
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 208000017442 Retinal disease Diseases 0.000 title abstract 2
- 206010038923 Retinopathy Diseases 0.000 title abstract 2
- 239000003481 heat shock protein 90 inhibitor Chemical class 0.000 title abstract 2
- 239000000411 inducer Substances 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 201000001119 neuropathy Diseases 0.000 title abstract 2
- 230000007823 neuropathy Effects 0.000 title abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 239000008196 pharmacological composition Chemical class 0.000 title abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title abstract 2
- ZQKILXWMFYEVQI-UHFFFAOYSA-N 2-(2-oxochromen-3-yl)acetamide Chemical class C1=CC=C2OC(=O)C(CC(=O)N)=CC2=C1 ZQKILXWMFYEVQI-UHFFFAOYSA-N 0.000 title 1
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical class NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 title 1
- -1 2h-pyran-2-yloxy Chemical group 0.000 title 1
- 208000002249 Diabetes Complications Diseases 0.000 title 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Chemical class 0.000 title 1
- 101150031823 HSP70 gene Chemical class 0.000 title 1
- 150000003869 acetamides Chemical class 0.000 title 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 title 1
- 101150052825 dnaK gene Chemical class 0.000 title 1
- 125000001033 ether group Chemical group 0.000 title 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 abstract 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016473P | 2014-06-24 | 2014-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016003276A1 true CL2016003276A1 (es) | 2017-05-26 |
Family
ID=53525293
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016003276A CL2016003276A1 (es) | 2014-06-24 | 2016-12-21 | Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía. |
| CL2018002367A CL2018002367A1 (es) | 2014-06-24 | 2018-08-17 | Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía. modificados como inhibidores de hsp90 e inductores de hsp70(div n° 3276-16) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002367A CL2018002367A1 (es) | 2014-06-24 | 2018-08-17 | Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía. modificados como inhibidores de hsp90 e inductores de hsp70(div n° 3276-16) |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10590065B2 (enExample) |
| EP (2) | EP4494702A3 (enExample) |
| JP (2) | JP6793640B2 (enExample) |
| KR (1) | KR102536408B1 (enExample) |
| CN (1) | CN106536498A (enExample) |
| AU (2) | AU2015279926B2 (enExample) |
| CA (2) | CA3289739A1 (enExample) |
| CL (2) | CL2016003276A1 (enExample) |
| CO (1) | CO2017000552A2 (enExample) |
| EA (1) | EA201790070A1 (enExample) |
| IL (1) | IL249712B (enExample) |
| MX (2) | MX388516B (enExample) |
| NZ (1) | NZ728482A (enExample) |
| SG (2) | SG11201610677XA (enExample) |
| WO (1) | WO2015200514A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| CN108478568B (zh) * | 2018-02-01 | 2020-08-28 | 华中农业大学 | 一种香豆素类化合物在制备单胺氧化酶抑制剂中的用途 |
| BR112020016205A2 (pt) * | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
| MX2025007723A (es) * | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
| KR102175125B1 (ko) * | 2018-12-28 | 2020-11-05 | 울산과학기술원 | 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002044192A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| AU2005301957B2 (en) | 2004-11-03 | 2012-02-23 | Department Of Health And Human Services | Novobiocin analogues as anticancer agents |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| JP5175191B2 (ja) | 2005-08-30 | 2013-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法 |
| EP2131656A4 (en) | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | phthalazine |
| EA019103B1 (ru) * | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5766617B2 (ja) * | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| CN102511153B (zh) | 2011-11-16 | 2014-09-03 | 华为技术有限公司 | 一种微波预失真信号生成方法和装置 |
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
-
2015
- 2015-06-24 CA CA3289739A patent/CA3289739A1/en active Pending
- 2015-06-24 EP EP24196960.9A patent/EP4494702A3/en not_active Withdrawn
- 2015-06-24 SG SG11201610677XA patent/SG11201610677XA/en unknown
- 2015-06-24 EA EA201790070A patent/EA201790070A1/ru unknown
- 2015-06-24 MX MX2019015888A patent/MX388516B/es unknown
- 2015-06-24 JP JP2017520743A patent/JP6793640B2/ja active Active
- 2015-06-24 CN CN201580033560.XA patent/CN106536498A/zh active Pending
- 2015-06-24 AU AU2015279926A patent/AU2015279926B2/en active Active
- 2015-06-24 CA CA2952029A patent/CA2952029C/en active Active
- 2015-06-24 US US15/321,289 patent/US10590065B2/en active Active
- 2015-06-24 NZ NZ728482A patent/NZ728482A/en unknown
- 2015-06-24 SG SG10201811574YA patent/SG10201811574YA/en unknown
- 2015-06-24 MX MX2016017133A patent/MX388515B/es unknown
- 2015-06-24 WO PCT/US2015/037478 patent/WO2015200514A2/en not_active Ceased
- 2015-06-24 EP EP15735815.1A patent/EP3160977A2/en not_active Withdrawn
- 2015-06-24 KR KR1020177001978A patent/KR102536408B1/ko active Active
-
2016
- 2016-12-21 CL CL2016003276A patent/CL2016003276A1/es unknown
- 2016-12-22 IL IL249712A patent/IL249712B/en active IP Right Grant
-
2017
- 2017-01-23 CO CONC2017/0000552A patent/CO2017000552A2/es unknown
-
2018
- 2018-08-17 CL CL2018002367A patent/CL2018002367A1/es unknown
-
2020
- 2020-01-29 US US16/776,091 patent/US11098008B2/en active Active
- 2020-11-10 JP JP2020186914A patent/JP7105851B2/ja active Active
-
2021
- 2021-02-15 AU AU2021200969A patent/AU2021200969B2/en active Active
- 2021-07-14 US US17/375,882 patent/US11708319B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002367A1 (es) | Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía. modificados como inhibidores de hsp90 e inductores de hsp70(div n° 3276-16) | |
| CU20150129A7 (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
| BR112014030091A2 (pt) | processos para produzir certos 2-(piridina-3-il)tiazóis | |
| MX2016006066A (es) | Pirrolo [1,2-f] [1,2,4] triazinas utiles para tratar infecciones por virus del sincitio respiratorio. | |
| CR20150425A (es) | Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes | |
| PH12015502116A1 (en) | Biaryl amide compounds as kinase inhibitors | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| CU24442B1 (es) | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina | |
| FR2995893B1 (fr) | Procede de production de butadiene-1,3 mettant en oeuvre la dimerisation de l'ethylene et la deshydrogenation des butenes obtenus | |
| MX2015002755A (es) | 1,3-dioxanomorfidas y 1,3-dioxanocodidas. | |
| CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| GT201500334A (es) | Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo | |
| CL2011002231A1 (es) | Forma cristalina vi de la agomelatina; proceso de preparacion; composicion farmaceutica; y su uso para tratar estres, ansiedad, trastornos del sueño, enfermedades cardiovasculares, esquizofrenia, fobia, depresion, enfermedades del sistema digestivo. | |
| CR20120287A (es) | Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| IN2015DN03145A (enExample) | ||
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| UY37947A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CR20140553A (es) | Compuestos de fenoxietil piperidina | |
| PH12017500351A1 (en) | N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors | |
| CL2015000580A1 (es) | Compuestos derivados de pirazol carboxamida, moduladores taar; composicion farmaceutica; proceso para obtenerlos; y su uso para el tratamiento terapeutico o profilactico de la depresion, trastornos de ansiedad, trastorno de hiperactividad con deficit de atencion, trastornos psicoticos, esquizofrenia y parkinson, entre otros. | |
| SV2011003846A (es) | Polimorfo b de la n-(2-aminofenil)-4- [n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) |